Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901356 | 0.93 | SMN1; SMN2 (0.51) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1624293 | 0.88 | SMN1; SMN2 (0.53) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13202732 | 0.88 | SMN1; SMN2 (0.53) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13705157 | 0.88 | CXCR4 (0.47) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8112938 | 0.87 | SMN1; SMN2 (0.50) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| Hydrochloric Acid SCHEMBL29277597 | 0.87 | SMN1; SMN2 (0.52) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| Hydrochloric Acid SCHEMBL29277599 | 0.87 | SMN1; SMN2 (0.52) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL10095049 | 0.84 | SMN1; SMN2 (0.53) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31701275 | 0.84 | SMN1; SMN2 (0.52) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29277609 | 0.84 | SMN1; SMN2 (0.52) | CXCR4SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CXCR4 3648/4885SMN1; SMN2 4811/4885NPC1 1165/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CXCR4 3648/4885SMN1; SMN2 4811/4885NPC1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.